Drug executive says regulatory obstacles delay new drugs, increase costs

07/16/2013 | BioSpectrum Asia

The actions of government regulatory agencies have contributed to declines in research productivity, discouraged investment and raised costs for the pharmaceutical industry throughout the world, according to Tony Alvarez, president of MSD KK in Japan, speaking at the in-Pharma Japan and Interphex Japan meetings in Tokyo. He alleged that such agencies, including the U.S. FDA, are deliberately blocking drug research and commercialization as a means of controlling costs.

View Full Article in:

BioSpectrum Asia

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT